Results 11 to 20 of about 6,458 (228)
A rare case of eptifibatide-induced thrombocytopenia [PDF]
Journal of Community Hospital Internal Medicine Perspectives, 2021 Eptifibatide is a glycoprotein (GP) IIb/IIIa receptor antagonist, used for the treatment of acute coronary syndrome with high-risk features or ongoing ischemia.
Khalil Kamar +4 more
doaj +4 more sources
Journal of Clinical and Preventive Cardiology, 2021 Eptifibatide inhibits platelet aggregation by reversibly binding to the platelet receptor glycoprotein (GP) IIb/IIIa of human platelets, thus preventing the binding of fibrinogen and adhesion proteins such as fibronectin, vitronectin, and von Willebrand ...
Savvy Nandal +2 more
doaj +2 more sources
Critical Analysis of Thrombocytopenia Associated With Glycoprotein IIb/IIIa Inhibitors and Potential Role of Zalunfiban, a Novel Small Molecule Glycoprotein Inhibitor, in Understanding the Mechanism(s) [PDF]
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2023 Thrombocytopenia is a rare but serious complication of the intravenous glycoprotein IIb/IIIa (GPIIb/IIIa; integrin αIIbβ3) receptor inhibitors (GPIs), abciximab, eptifibatide, and tirofiban. The thrombocytopenia ranges from mild (50 000–100 000 platelets/
Sem A. O. F. Rikken +4 more
doaj +2 more sources
Stabilization of eptifibatide by cosolvents [PDF]
International Journal of Pharmaceutics, 2001 Eptifibatide is a potent and highly specific inhibitor of platelet receptor glycoprotein IIb/IIIa and is indicated in the treatment of acute coronary syndrome. The commercial product Integrilin(R) (eptifibatide) Injection requires a cold/refrigerator storage condition.
Luwei Zhao, Samuel H. Yalkowsky
openalex +4 more sources
Acta Medica Iranica, 2020 Introduction: Platelets activation and aggregation play a major role in thrombosis formation of coronary arteries in patients with Acute Coronary Syndrome (ACS) and is responsible for most ischemic complications during PCI.
tooran makhdoumi
doaj +2 more sources
Cardiovascular Diabetology, 2008 Background The use of abciximab (c7E3 Fab) or eptifibatide improves clinical outcomes in diabetics undergoing percutaneous coronary intervention. These β3 integrin inhibitors antagonize fibrinogen binding to αIIbβ3 integrins on platelets and ligand ...
Huang Jianhua +3 more
doaj +3 more sources
Clinical and economic studies of eptifibatide in coronary stenting
Therapeutics and Clinical Risk Management, 2014 Tilak Pasala, Prasongchai Sattayaprasert, Pradeep K Bhat, Ganesh Athappan, Sanjay Gandhi The Heart and Vascular Center, Case Western Reserve University/MetroHealth, Cleveland, OH, USA Abstract: Platelet adhesion and aggregation at the site of coronary ...
Pasala T +4 more
doaj +5 more sources
Comparison of eptifibatide and abciximab with decision analysis [PDF]
American Journal of Health-System Pharmacy, 2001 Dorothy H. Wong
openalex +4 more sources
Profound Thrombocytopenia Associated With Administration of Eptifibatide [PDF]
Laboratory Medicine, 2007 Acute profound thrombocytopenia may be associated with the administration of eptifibatide, a glycoprotein antagonist. A case report of a 61-year-old male is presented. The reported incidence of acute profound thrombocytopenia associated with eptifibatide is 0.1% to 1.0% and usually occurs within 24 hours following therapy.
Gifford Lum, Paula Szuflad
openalex +2 more sources
Addition of eptifibatide and manual thrombus aspiration to ticagrelor does not improve long-term survival after STEMI treated with primary PCI [PDF]
Frontiers in PharmacologyBackground: Current guidelines recommend that glycoprotein IIb/IIIa inhibitor (GPI) and manual aspiration thrombectomy should not be routinely used in patients with ST-segment elevation myocardial infarction (STEMI) treated by primary percutaneous ...
Paul-Adrian Călburean +11 more
doaj +2 more sources